Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ELTP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -0.1146M
March 31, 2026 -0.0415M
December 31, 2025 -0.0336M
September 30, 2025 -0.1165M
June 30, 2025 -4.131M
March 31, 2025 -0.137M
December 31, 2024 -0.1931M
September 30, 2024 -0.3207M
June 30, 2024 -0.1749M
March 31, 2024 -0.3614M
December 31, 2023 -0.0307M
September 30, 2023 -0.1795M
June 30, 2023 3.957M
March 31, 2023 -12.50M
December 31, 2022 -0.0774M
September 30, 2022 2.385M
June 30, 2022 11.90M
March 31, 2022 -0.0942M
December 31, 2021 -0.1539M
September 30, 2021 -0.2665M
June 30, 2021 -0.1525M
March 31, 2021 -1.286M
December 31, 2020 -0.1505M
September 30, 2020 -0.245M
June 30, 2020 0.8114M
Date Value
March 31, 2020 0.5008M
December 31, 2019 -0.072M
September 30, 2019 0.1468M
June 30, 2019 0.114M
March 31, 2019 0.3851M
December 31, 2018 0.2643M
September 30, 2018 0.5633M
June 30, 2018 0.3542M
March 31, 2018 0.8475M
December 31, 2017 0.0813M
September 30, 2017 0.3368M
June 30, 2017 0.4054M
March 31, 2017 1.680M
December 31, 2016 1.723M
September 30, 2016 2.317M
June 30, 2016 2.351M
March 31, 2016 3.373M
December 31, 2015 0.8105M
September 30, 2015 1.600M
June 30, 2015 2.978M
March 31, 2015 3.646M
December 31, 2014 3.637M
September 30, 2014 4.260M
June 30, 2014 1.204M
March 31, 2014 7.401M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Nektar Therapeutics 364.57M
Daré Bioscience, Inc. 0.9512M
Eton Pharmaceuticals, Inc. -0.076M
ANI Pharmaceuticals, Inc. -4.647M
Corcept Therapeutics, Inc. -2.037M